The transmissible spongiform encephalopathies are characterized by the conversion of the protease-sensitive prion protein (PrPsen) into a protease-resistant isoform (PrPres) associated with the neuropathogenic process in vivo. Recently, PrPres has been shown to be capable of directly inducing the conversion of PrPsen to PrPres in a cell-free in vitro system. In the present experiments, various PrP peptides were studied for their ability to enhance or inhibit this cell-free conversion reaction. None of the synthetic peptides was able to confer protease-resistance to the labeled PrPsen molecules on their own. On the contrary, peptides from the central part of the hamster PrP sequence from 106 to 141 could completely inhibit the conversion induced by preformed PrPres. The presence of residues 119 and 120 from the highly hydrophobic sequence AGAAAAGA (position 113 to 120) was crucial for an efficient inhibitory effect. Fourier transform infrared spectroscopy analysis indicated that inhibitory peptides formed high ␤-sheet aggregates under the conditions of the conversion reaction, but this was also true of certain peptides that were not inhibitory. Thus, the potential to form ␤-sheeted aggregates may be necessary, but not sufficient, for peptides to act as inhibitors of PrPres formation. Clearly, the amino acid sequence of the peptide is also important for inhibition. The sequence specificity of the inhibition is consistent with the idea that residues in the vicinity of positions 106 -141 of PrPres and/or PrPsen are critically involved in the intermolecular interactions that lead to PrPres formation.
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Transmissible spongiform encephalopathies (TSE) 1 are fatal neurodegenerative diseases including sporadic and familial Creutzfeldt-Jakob disease, kuru and Gerstmann-Strä usslerScheinker syndrome in humans, scrapie in sheep, and bovine spongiform encephalopathy in cattle (1, 2) . TSE are characterized by the formation and accumulation of an abnormal proteinase K-resistant isoform (PrPres) of normal protease-sensitive host-encoded prion protein (PrPsen). PrPres is formed from PrPsen by a post-translational process involving conformational changes, a higher ␤-sheet content, and the formation of macromolecular aggregates (3) (4) (5) . PrPres is closely associated with TSE-mediated brain pathology, suggesting a crucial role of PrPres in the pathogenic process. However, in the absence of PrPsen expression in the brain tissue of recipients of scrapieinfected neurografts, no pathology outside the graft itself was observed, demonstrating that PrPres and PrPsen are both required for the pathology (6) . Both cross-species transmission in vivo and efficient PrPres accumulation in vitro require a high degree of sequence homology between PrPres and PrPsen molecules. For example, in scrapie-infected neuroblastoma cells, point mutations at three positions, 108, 111, and 138, in the mouse PrP sequence are sufficient to completely block the formation of PrPres (7, 8) . In a cell-free in vitro system, PrPres induces the conversion of PrPsen to PrPres (9) . This interaction between PrPres and PrPsen occurs with species and strain specificities that mimic TSE species barrier effects and strain differences in vivo (10 -13) . Collectively, these in vivo and in vitro observations strongly suggest that precise direct interactions between PrPres and PrPsen are critical in PrPres formation and TSE pathogenesis.
In previous experiments, small synthetic peptides containing certain PrP sequences spontaneously aggregated to form fibrils with a high degree of ␤-sheet secondary structure (14 -17) . Moreover, other synthetic PrP peptides were shown to interact with PrPsen molecules, forming an aggregated complex with increased protease resistance (18, 19) . In the current study, peptides from a variety of locations in the hamster PrP sequence were studied for their ability to influence the generation of PrPres under cell-free conditions. A group of peptides from the central portion of the PrP molecule having high ␤-sheet content displayed a strong inhibitory effect on the cell-free conversion assay. Based on these results, we propose the existence of sites on the central part of the PrP molecule that allow a specific binding between PrPsen and PrPres as a first step in the conversion of PrPsen to PrPres.
EXPERIMENTAL PROCEDURES
Peptides-The following peptides were synthesized by the laboratory of molecular structure of NIAID, NIH, Rockville MD: hamster P106 -128 (KTNMKHMAGAAAAGAVVGGLGGY), P109 -141 (MKHMAGA-AAAGAVVGGLGGYMLGSAMSRPMMHF), P113-141 (AGAAAAGAV-VGGLGGYMLGSAMSRPMMHF), and P121-141 (VVGGLGGYMLGS-AMSRPMMHF). Peptides were Ͼ95% pure, and analysis by high pressure liquid chromatography revealed only a single peak. Alzheimer's disease amyloid-␤ protein fragment 1-40 (A␤-(1-40)) was purchased from Sigma. Lyophilized peptides were dissolved in deionized water at a concentration of 2 mM, distributed into 20-l aliquots, and stored at Ϫ20°C.
Labeling and Purification of PrPsen-The radiolabeling and the purification of the 35 S-PrPsen were performed as described previously by Raymond et al. (13) . Briefly, 90% confluent cells were cultured for 30 min at 37°C in 1.5 ml of methionine/cysteine-deficient medium followed by a 90 -120-min incubation with 1.4 mCi of [
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25-cm 2 flask. Then the cells were washed twice with phosphate-buffered saline (20 mM sodium phosphate, pH 7.4, 130 mM NaCl) and lysed in 1.5 ml of lysis buffer containing 5 mM Tris-HCl, pH 7.4, 140 mM NaCl, 5 mM EDTA, 0.5% sodium deoxycholate, and 0.5% Triton X-100. The proteins were precipitated by the addition of 5 volumes of methanol, resuspended in detergent-lipid complexes, and immunoprecipitated by overnight incubation at 4°C with anti-PrP 3F4 monoclonal antibody (20) . Immune complexes were collected by binding to protein A-Sepharose beads. Radiolabeled PrPsen was eluted from Sepharose beads using 0.1 M acetic acid and stored at 4°C until use. The 35 S-labeled hamster PrPsen used in this study was the glycophosphatidylinositolnegative form ( 35 S-HaPrPsen) described previously (9) . Purification and Analysis of PrPres-PrPres was purified from brains of scrapie-infected Syrian golden hamsters by detergent lysis and differential centrifugation (21) . Hamsters were infected 70 days before with the hamster scrapie strain 263K. The yield of PrPres was determined by Western blotting using a rabbit polyclonal PrP antiserum (R27) raised against a synthetic hamster PrP peptide (residues 89 -103) (22) . The purity of the preparations was estimated at 50 -60% by silver-staining of SDS-PAGE gels. The hamster PrPres preparation (HaPrPres) was then diluted to 1 mg/ml in phosphate-buffered saline containing 1% sulfobetaine 3-14 and stored at Ϫ20°C.
Cell-free Conversion Assay-The cell-free conversion reaction was performed as described previously (9, 13) . Briefly, purified PrPres was partially denatured with 2.5 M guanidine hydrochloride for 30 -60 min at 37°C. An aliquot of 200 ng of HaPrPres, typically 8 l, was then incubated for 40 h at 37°C with ϳ1 ng of immunopurified 35 S-PrPsen (ϳ12,000 cpm/reaction) in a final volume of 20 l of conversion buffer (50 mM sodium citrate, pH 6, 5 mM cetylpyridinium chloride, 0.625% N-lauryl sarcosinate) in the presence or absence of peptides. At the end of the incubation time, each reaction was split 1:10, the major fraction was digested with 100 g/ml proteinase K (PK) in Tris-saline buffer (50 mM Tris, pH 8, 130 mM NaCl) for 1 h at 37°C, and the minor part (ϪPK) was reserved as an undigested control. The PK reaction was stopped by the addition of 10 l of a mixture of 4 mg/ml thyroglobulin, 20 mM Pefabloc (Boehringer-Mannheim) to each fraction (ϩ and ϪPK). Samples were then precipitated in 5 volumes of methanol and centrifuged for 20 min at 14,000 ϫ g. The pellets were resuspended in sample buffer (65 mM Tris-HCl, pH 6.8, 5% glycerol, 5% SDS, 4 M urea, 5% ␤-mercaptoethanol, 0.5% bromphenol blue), boiled 5 min, and analyzed by SDS-PAGE on NOVEX pre-cast gels. The percent of the conversion was calculated by the ratio between the PK-resistant 35 S-labeled bands of approximate molecular masses 28 -30 kDa and the nondigested 35 SPrPsen as quantified by phosphor autoradiographic imager analysis. At the concentration used, none of the peptides affected the PK digestion of PrPres (data not shown).
Sedimentation Experiments-Immunopurified 35 S-HaPrPsen (12,000 cpm/reaction) was incubated for 24 h at 37°C with 200 ng of 2.5 M guanidine hydrochloride-pretreated HaPrPres in the absence or presence of indicated concentrations of peptides P-(109-141), P-(113-141), P-(121-141), and A␤-(1-40). At the end of the incubation time, the samples were centrifuged at room temperature for 20 min at 14,000 ϫ g. The supernatants and the pellets were separately collected and methanol-precipitated before SDS-PAGE analysis and phosphor autoradiographic imager quantification.
Fourier Transform Infrared Spectroscopy-The dried peptides were rehydrated by mixing with conversion buffer and incubated for 4 -60 h at room temperature before Fourier transform infrared spectroscopy analysis. Samples (6 l) were loaded into variable path-length cells with CaF 2 plates adjusted to a path length of 6 m. After purging the sample chamber to reduce the water vapor contribution, spectra were collected with a Perkin-Elmer system 2000 spectrometer. Spectral parameters were as follows: 254 scans; 4-cm Ϫ1 resolution; 1 cm/sec optical path difference velocity; Kaiser-Bessel apodization. Buffer spectra were subtracted from peptide spectra to give a flat base line in the 1800 -2200-cm Ϫ1 region. A water vapor spectrum was then subtracted to minimize the water vapor bands in the 1750 -1850-cm Ϫ1 region.
RESULTS

Inhibition of Conversion by Hamster PrP Peptides-Various
PrP synthetic peptides, whose localization on the primary hamster PrP sequence is shown in Fig. 1A , were tested for effects on the in vitro conversion of metabolically labeled PrPsen molecules into PrPres. The peptides were used in the cell-free conversion assay at a final concentration of 0.8 mM. As shown in Fig. 1B , the non-PK-treated 35 S-HaPrPsen appeared as a double band with molecular masses of 30 and 28.5 kDa, corresponding to mono-or unglycosylated forms of the molecule, respectively. In the absence of HaPrPres, no PK-resistant bands were seen in the control experiment. In those conditions, none of the peptides was able by itself to promote the conversion of 35 S-HaPrPsen to a PK-resistant form (Fig. 1B , lanes marked Ϫ). In the presence of 200 ng of HaPrPres, two PKresistant 35 S-labeled bands were obtained with molecular masses of 24 and 20 kDa (Fig. 1B, lanes marked ϩ) . However, two synthetic hamster peptides, P-(106 -128) and P-(109 -141), were able to inhibit the formation of 35 S-labeled PK-resistant PrP bands. A third peptide, P-(89 -103), partially inhibited the conversion, and six other peptides, P-(23-37), P-(57-64), P-(57-72), P-(57-80), P-(139 -170), and P-(218 -232) failed to inhibit the conversion.
The quantitative effect of peptide concentration on the cellfree conversion was examined further using the two most inhibitory hamster peptides (Fig. 2A) . The peptide concentrations required to inhibit 50% of the hamster PrP conversion reaction (IC 50 ) were calculated to be 230 and 30 M for the peptides P-(106 -128) and P-(109 -141), respectively (Fig. 2B ). In contrast, an unrelated amyloidogenic peptide, Alzheimer's A␤-(1-40), was unable to inhibit the PrPsen to PrPres conversion at all concentrations tested (Figs. 2, A and B) . These results clearly demonstrated that the conversion was specifically inhibited by peptides from the central portion of PrP molecule.
Importance of the 8-Amino Acid Sequence 113-120 -The PrP synthetic peptide AGAAAAGA from position 113 to 120 has been described as the most highly amyloidogenic peptide in the protein (14) . To assess the influence of the AGAAAAGA sequence contained in both P-(106 -128) and P-(109 -141), we synthesized two peptides differing only in this hydrophobic sequence, P-(113-141) and P-(121-141). The P-(113-141) peptide sequence efficiently inhibited the in vitro conversion with an IC 50 value of 40 M (Figs. 3, A and B) . In contrast, the P-(121-141) peptide failed to inhibit the conversion at all of the concentrations used (Figs. 3, A and B) . When incubated with the labeled PrPsen in the absence of PrPres, none of these peptides conferred PK resistance to PrPsen molecules (Fig. 3A) . Thus, the hydrophobic sequence from 113 to 120 appeared to be essential to the inhibitory effect of peptides from this region of PrP.
To find the minimal number of hydrophobic amino acid residues from the AGAAAAGA sequence required for inhibiting the conversion reaction, three partially deleted peptides were synthesized (P-(119 -141), P-(117-141), and P-(115-141), Fig.  3B ). The presence of two of these hydrophobic residues was sufficient to allow the inhibition of the conversion because P-(119 -141) was nearly as inhibitory as P-(113-141). However, the IC 50 was decreased up to 3-fold as additional hydrophobic amino acid residues were added (Fig. 3B) .
Conformational Analysis of Inhibitory Versus Noninhibitory Peptides-Fourier transform infrared spectroscopy was used to compare the conformations of the PrP and A␤-(1-40) peptides to see if there was a correlation between inhibitory efficacy and conformation. For this purpose, peptides were incubated for 4 -60 h in conversion buffer without any PrPsen or PrPres. Fourier transform infrared spectra of peptides incubated for 24 h at a concentration of 2 mM are shown in Fig. 4 . Five of the peptides (P-(106 -128), P-(109 -141), P-(113-141), P-(121-141), and A␤-(1-40)) showed prominent absorbance maxima at ϳ1630 cm Ϫ1 that were indicative of a high ␤-sheet content. For P-(109 -141), this predominant absorbance at 1630 cm Ϫ1 was maintained down to concentrations of 0.2 mM. These same five The samples were PK-treated as described under "Experimental Procedures" before SDS-PAGE analysis except the first lane on the left panel, which represents one-tenth of a conversion reaction and was nondigested with PK. B, hamster P-(113-141), P-(115-141), P-(117-141), P-(119 -141), and P-(121-141) primary sequence peptides and dose response curves of the inhibition of the conversion reactions. The data represent the mean of three independent experiments and are plotted as the percentage of the ratio between the conversion in the presence of the peptide and the control conversion reaction. The sequences of the peptides used are indicated above the graph.
peptides were at least partially insoluble as each formed a visible particulate suspension. Two other PrP peptides (P-(89 -103) and P-(218 -232)) maintained clear solutions and had absorbance maxima near 1667 cm Ϫ1 , with no evidence of the ␤-sheet absorbance at ϳ1630 cm
Ϫ1
. Although all the inhibitory peptides showed evidence of a high ␤-sheet content, other peptides, such as P-(121-141) and A␤-(1-40), showed a similar ␤-sheet content but gave no inhibition of conversion. Thus, the potential to form a high amount of ␤-sheet structure might be necessary, but not sufficient, for the specific inhibitory activity of any given peptide.
Peptide Sedimentation Studies-Considering the propensity of hydrophobic PrP peptides to aggregate in vitro, we investigated whether the inhibition of the conversion could be explained by peptide-induced aggregation of 35 S-HaPrPsen, which might prevent conversion of this precursor protein. For this purpose, conversion reaction mixtures were centrifuged in the presence or absence of various peptides, and pellet and supernatant fractions were analyzed for 35 S-HaPrPsen (Fig. 5) . Whereas is not converted into a proteinase K-resistant isoform after expression in scrapie-infected mouse neuroblastoma cells. In our current studies, the presence of the corresponding hamster sequence from 113 to 120 correlated with the inhibition of the conversion reaction. Indeed, all the peptides having this sequence such as P-(106 -128), P-(109 -1410, and P-(113-141) had an inhibitory effect, whereas P-(121-141) did not exhibit this property (Figs. 3, A and B) . Interestingly, residues 119 and 120 appeared to be most critical to the inhibition as P-(119 -141) was nearly as effective as P-(113-141) (Fig. 3B) . Peptides from the amino-terminal region such as P-(23-37), P-(57-64), P-(57-72), and P-(57-80) and from the carboxyl-terminal region such as P-(139 -170) and P-(218 -232) did not inhibit the conversion reaction. Only P-(89 -103) was able to slightly decrease the conversion when incubated at the high concentration of 0.8 mM (Fig. 1B) . P-(89 -103) is contained in the PKresistant core of PrPres, and its location is adjacent to the most inhibitory peptide sequences. These data suggested that, unlike the central portion of PrPres, the amino-and the carboxylterminal regions of the molecule are less involved in the intermolecular interactions resulting in PrPres formation. This explanation is consistent with the fact that the carboxyl-and amino-terminal portions of PrPres are more sensitive to the PK digestion than the central part (21, 24) .
In our experiments, the presence of PrP amino acid residues from 113 to 120 were required for maximal inhibition, but other amino acid residues are likely also to be involved in the specific intermolecular interaction. The adjacent sequence from residues 129 to 141 seemed to play an important modulatory role in the inhibition of conversion, since P-(106 -128) was significantly less inhibitory compared with P-(109 -141) (Figs. 2, A  and B) . This interpretation is consistent with a previous report showing that a point mutation at position 138 could block the accumulation of PrPres in the mouse neuroblastoma cell system (8) . Together these results suggest that the region of residue 138 in the PrP polypeptide is important in the intermolecular interactions leading to PrPres formation.
The mechanism of action of the inhibitory peptides is still unclear. Possibly the inhibitory peptides mimic the structure of PrPres and competitively bind to PrPsen molecules to block the conversion process. Alternatively, peptides could bind to PrPres itself, blocking further interaction with PrPsen. In the conversion reaction buffer, the peptides P-(106 -128), P-(109 -141), and P-(113-141) possessed a high ␤-sheet content reminiscent to brain-derived PrPres (3) (4) (5) . Whether the active state of the inhibitory peptides is the soluble or aggregated form is not known. However, their mechanism of action cannot be explained merely by their tendency to form ␤-sheet structure and sedimentable aggregates with PrPsen, since noninhibitory FIG. 4 . Fourier transform infrared spectroscopy. The peptides were incubated in conversion buffer for 24 h at room temperature as described under "Experimental Procedures." Buffer spectra were subtracted from peptide spectra to give a flat base line in the 1800 -2200 cm Ϫ1 region. A water spectrum was then subtracted to minimize the water vapor bands in the 1750 -1850 cm Ϫ1 region. peptides such as P-(121-141) and A␤-(1-40) displayed the same biochemical properties.
In our hands, none of the tested peptides were capable of conferring PK resistance to 35 S-PrPsen (Fig. 1B) . Using slightly different conditions, other authors have shown that incubation of hamster PrPsen with hamster peptide P-(90-145) resulted in the formation of a PK-resistant, sedimentable PrPsen⅐peptide complex (18, 19) . Upon PK digestion, no shift of the molecular mass of this PrPsen⅐peptide complex was reported. Thus, this complex may be a large aggregate unaccessible to PK, in contrast to brain-derived PrPres and PrPres formed in our cell-free conversion experiments, which loses ϳ67 amino-terminal amino acid residues (6-7 kDa) with PK treatment.
Studies using PrP may suggest new approaches for possible therapeutic intervention. The ability of PrP peptides to inhibit the accumulation of PrPres in vivo remains to be established. Nevertheless, PrP peptides dispensed by direct injection or delivered by gene therapy might provide specific therapeutic treatment for TSE diseases. Furthermore, structural analysis of the minimal peptide sequence required for inhibition of conversion might lead to development of nonpeptide compounds with therapeutic potential.
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